{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT02672306",
      "NCTIdAliasList": {
        "NCTIdAlias": [
          "NCT02513706"
        ]
      },
      "OrgStudyIdInfo": {
        "OrgStudyId": "UCMSC-1"
      },
      "Organization": {
        "OrgFullName": "South China Research Center for Stem Cell and Regenerative Medicine",
        "OrgClass": "OTHER"
      },
      "BriefTitle": "Safety and Exploratory Efficacy Study of UCMSCs in Patients With Alzheimer's Disease",
      "OfficialTitle": "Clinical Study on the Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Injection in the Treatment of Mild and Moderate Alzheimer's Disease",
      "Acronym": "SEESUPAD"
    },
    "StatusModule": {
      "StatusVerifiedDate": "February 2018",
      "OverallStatus": "Unknown status",
      "LastKnownStatus": "Active, not recruiting",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "October 20, 2017",
        "StartDateType": "Actual"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "October 2018",
        "PrimaryCompletionDateType": "Anticipated"
      },
      "CompletionDateStruct": {
        "CompletionDate": "October 2019",
        "CompletionDateType": "Anticipated"
      },
      "StudyFirstSubmitDate": "January 24, 2016",
      "StudyFirstSubmitQCDate": "January 29, 2016",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "February 3, 2016",
        "StudyFirstPostDateType": "Estimate"
      },
      "LastUpdateSubmitDate": "April 25, 2018",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "April 26, 2018",
        "LastUpdatePostDateType": "Actual"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Sponsor"
      },
      "LeadSponsor": {
        "LeadSponsorName": "South China Research Center for Stem Cell and Regenerative Medicine",
        "LeadSponsorClass": "OTHER"
      },
      "CollaboratorList": {
        "Collaborator": [
          {
            "CollaboratorName": "Guangzhou General Hospital of Guangzhou Military Command of PLA",
            "CollaboratorClass": "UNKNOWN"
          },
          {
            "CollaboratorName": "Third Affiliated Hospital, Sun Yat-Sen University",
            "CollaboratorClass": "OTHER"
          }
        ]
      }
    },
    "OversightModule": {
      "OversightHasDMC": "Yes",
      "IsFDARegulatedDrug": "No",
      "IsFDARegulatedDevice": "No"
    },
    "DescriptionModule": {
      "BriefSummary": "The primary purpose of this study is to evaluate the safety and the efficacy of (Human Umbilical Cord-Derived Mesenchymal Stem Cells) UCMSCs for patients with Alzheimer's disease (AD).",
      "DetailedDescription": "Study Type: Interventional Study Design: Treatment, Parallel Assignment, Double Blind (Subject, Outcomes Assessor), Randomized, Safety/ Efficacy Study Official Title: Multicenter, Randomized, Double-blind, Placebo Controlled Trial of UCMSCs in Subjects With Alzheimer's Disease"
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Alzheimer's Disease"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Phase 1",
          "Phase 2"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "Randomized",
        "DesignInterventionModel": "Parallel Assignment",
        "DesignPrimaryPurpose": "Treatment",
        "DesignMaskingInfo": {
          "DesignMasking": "Double",
          "DesignWhoMaskedList": {
            "DesignWhoMasked": [
              "Participant",
              "Care Provider"
            ]
          }
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "16",
        "EnrollmentType": "Anticipated"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "UCMSCs",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "Subjects with Alzheimer's Disease Intervention: UCMSCs",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Biological: UCMSCs"
              ]
            }
          },
          {
            "ArmGroupLabel": "Placebo",
            "ArmGroupType": "Placebo Comparator",
            "ArmGroupDescription": "Subjects with Alzheimer's Disease Intervention: Placebo (normal saline)",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Biological: Placebo"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Biological",
            "InterventionName": "UCMSCs",
            "InterventionDescription": "Biological: Human UCMSCs 20 million cells per subject (0.5×10^6 UCMSCs per kg) intravenous injection Infusion number: 8 (Once every two weeks)",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "UCMSCs"
              ]
            },
            "InterventionOtherNameList": {
              "InterventionOtherName": [
                "Human Umbilical Cord Derived Mesenchymal"
              ]
            }
          },
          {
            "InterventionType": "Biological",
            "InterventionName": "Placebo",
            "InterventionDescription": "Subjects with Alzheimer's Disease placebo comparator (normal saline) intravenous injection Infusion number: 8 (Once every two weeks)",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Placebo"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "Change in Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog)Score",
            "PrimaryOutcomeDescription": "A psychometric instrument that evaluates memory, attention, reasoning, language, orientation, and praxis.",
            "PrimaryOutcomeTimeFrame": "36 weeks from post-administration"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "Change in Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog)Score",
            "SecondaryOutcomeDescription": "A psychometric instrument that evaluates memory, attention, reasoning, language, orientation, and praxis.",
            "SecondaryOutcomeTimeFrame": "10 weeks,18 weeks,24 weeks,48weeks from post-administration"
          },
          {
            "SecondaryOutcomeMeasure": "Change in Mini-Mental State Examination (MMSE) Score",
            "SecondaryOutcomeDescription": "A frequently used screening instrument for Alzheimer's disease drug studies. It evaluates orientation, memory, attention, concentration, naming, repetition, comprehension, and ability to create a sentence and to copy two intersecting polygons.",
            "SecondaryOutcomeTimeFrame": "10 weeks,18 weeks,36 weeks，24 weeks,48weeks from post-administration"
          },
          {
            "SecondaryOutcomeMeasure": "Change in Clinician's Interview-Based Impression of Change (CIBIC-plus) Score",
            "SecondaryOutcomeTimeFrame": "10 weeks,18 weeks,24 weeks,36 weeks，48weeks from post-administration"
          },
          {
            "SecondaryOutcomeMeasure": "Change in Alzheimer's Disease Cooperative Study Activities of Daily Living Inventory (ADCS-ADL) Score",
            "SecondaryOutcomeDescription": "ADCS-ADL assesses functional performance in subjects with Alzheimer's disease. In a structured interview format, informants are queried as to whether subjects attempted each item in the inventory during the prior 4 weeks and their level of performance. The ADCS-ADL scale discriminates well between normal controls and mild AD patients. It has good test-retest reliability. The ADCS-ADL includes some items from traditional basic ADL scales (e.g., grooming, dressing, walking, bathing, feeding, toileting) as well as items from instrumental activities of daily living scales (e.g., shopping, preparing meals, using household appliances, keeping appointments, reading).",
            "SecondaryOutcomeTimeFrame": "10 weeks,18 weeks,24 weeks,36 weeks，48weeks from post-administration"
          },
          {
            "SecondaryOutcomeMeasure": "Change in Neuropsychiatric Inventory (NPI) Score",
            "SecondaryOutcomeDescription": "The NPI is a well-validated, reliable, multi-item instrument to assess psychopathology and behavior in AD based on interview with the informant.",
            "SecondaryOutcomeTimeFrame": "10 weeks,18 weeks,24 weeks,36 weeks，48weeks from post-administration"
          },
          {
            "SecondaryOutcomeMeasure": "Changes in AD Biomarkers",
            "SecondaryOutcomeDescription": "Plasma beta-amyloid proteins will be collected from blood samples obtained.",
            "SecondaryOutcomeTimeFrame": "36 weeks from post-administration"
          }
        ]
      },
      "OtherOutcomeList": {
        "OtherOutcome": [
          {
            "OtherOutcomeMeasure": "Symptoms Checklist and Adverse Event Assessment",
            "OtherOutcomeDescription": "Adverse events and symptoms checklist are used to monitor signs or symptoms that may or may not be related to study medication, abnormalities detected during physical examination, or clinical significant laboratory abnormalities.",
            "OtherOutcomeTimeFrame": "From Day0（administration）to 48 weeks post-administration."
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nAges 50 to 80, male and female.\nA diagnosis of probable AD and Mixed Dementia according to the criteria of the NINCDS-ADRDA\nTreatment with other cholinesterase inhibitors, such as a stable dose of donnepiazide tablets (5mg/ day or 10mg/ day) or the use of heavy tartaric acid karbalin capsules, is currently being used.\nMMSE score between 10 and 26.\nVoluntarily participating subject who sign the Inform Concent\n\nExclusion Criteria:\n\nCaused by other reasons of dementia (vascular dementia, infectious disease of the central nervous system (such as HIV, syphilitic dementia), g - she's disease, Parkinson's disease, Lou gehrig's disease, huntington's disease DLB, traumatic brain dementia, other physical and chemical factors (such as: drug poisoning, alcoholism, carbon monoxide poisoning and other dementia), important body disease (such as hepatic encephalopathy, pulmonary encephalopathy dementia), intracranial placeholder lesions, endocrine system disease, such as thyroid disease, parathyroid disease), and vitamins and other causes of dementia)\nThe Hamilton depression scale (HAMD) score > 17, or patients with a history of depression or other psychiatric or psychiatric disorders.\nThe Hachinski ischemic index scale (HIS) scored > 4.\nThe brief intelligence status examination scale (MMSE) score of 10 patients.\nLiver function (ALT, AST) exceeded the normal range limit of 1.5 times, SCr exceeded normal range upper limit, white blood cell count < 4.0 x 109/L or platelet < 100 x 109/L, hemoglobin < 100g/L.\nPatients with type 1 diabetes, obstructive pulmonary disease (copd) or asthma, vitamin B12 or folate deficiency patients, not control good digestion, liver, kidney, endocrine and cardiovascular system diseases (especially sick sinus syndrome and conduction block), patients with HIV/AIDS, syphilis, active tuberculosis, etc.\nA person with cancer or a history of cancer.\nPeople with a clinically significant history of stroke, who have had a seizure or a head injury in the past two years, have caused the disorder.\nThere is a history of congestive heart failure or a history of myocardial infarction, and a blood disease in two years.\nDrug clinical trials were performed within 3 months of screening.\nAnti-ad agents are being used in addition to the programme requirements.\nThe use of stem cell therapy in half a year.\nPeople with history of alcoholism and substance abuse, allergies, or history of allergies.\nPatients who had been hospitalized for more than 3 months before screening. of allergies.\nThe researchers think it is inappropriate to participate in this clinical trial.",
      "HealthyVolunteers": "No",
      "Gender": "All",
      "MinimumAge": "50 Years",
      "MaximumAge": "85 Years",
      "StdAgeList": {
        "StdAge": [
          "Adult",
          "Older Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "South China Research Center for Stem Cell and Regenerative Medicine,South China Institute of Biomedicine",
            "LocationCity": "Guangzhou",
            "LocationState": "Guangdong",
            "LocationZip": "510320",
            "LocationCountry": "China"
          }
        ]
      }
    },
    "IPDSharingStatementModule": {
      "IPDSharing": "Yes"
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000000544",
            "ConditionMeshTerm": "Alzheimer Disease"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000003704",
            "ConditionAncestorTerm": "Dementia"
          },
          {
            "ConditionAncestorId": "D000001927",
            "ConditionAncestorTerm": "Brain Diseases"
          },
          {
            "ConditionAncestorId": "D000002493",
            "ConditionAncestorTerm": "Central Nervous System Diseases"
          },
          {
            "ConditionAncestorId": "D000009422",
            "ConditionAncestorTerm": "Nervous System Diseases"
          },
          {
            "ConditionAncestorId": "D000024801",
            "ConditionAncestorTerm": "Tauopathies"
          },
          {
            "ConditionAncestorId": "D000019636",
            "ConditionAncestorTerm": "Neurodegenerative Diseases"
          },
          {
            "ConditionAncestorId": "D000019965",
            "ConditionAncestorTerm": "Neurocognitive Disorders"
          },
          {
            "ConditionAncestorId": "D000001523",
            "ConditionAncestorTerm": "Mental Disorders"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M3037",
            "ConditionBrowseLeafName": "Alzheimer Disease",
            "ConditionBrowseLeafAsFound": "Alzheimer's Disease",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M6056",
            "ConditionBrowseLeafName": "Dementia",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M4356",
            "ConditionBrowseLeafName": "Brain Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M4894",
            "ConditionBrowseLeafName": "Central Nervous System Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M22155",
            "ConditionBrowseLeafName": "Tauopathies",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M20711",
            "ConditionBrowseLeafName": "Neurodegenerative Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M20989",
            "ConditionBrowseLeafName": "Neurocognitive Disorders",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M3967",
            "ConditionBrowseLeafName": "Mental Disorders",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M13625",
            "ConditionBrowseLeafName": "Psychotic Disorders",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "T2192",
            "ConditionBrowseLeafName": "Familial Alzheimer Disease",
            "ConditionBrowseLeafAsFound": "Alzheimer's Disease",
            "ConditionBrowseLeafRelevance": "high"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC10",
            "ConditionBrowseBranchName": "Nervous System Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "BXM",
            "ConditionBrowseBranchName": "Behaviors and Mental Disorders"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "Rare",
            "ConditionBrowseBranchName": "Rare Diseases"
          }
        ]
      }
    }
  }
}